These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 10907947)

  • 1. The addition of low-dose leucovorin to the combination of 5-fluorouracil- levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. IKN Colon Trial Group.
    Bleeker WA; Mulder NH; Hermans J; Otter R; Plukker JT
    Ann Oncol; 2000 May; 11(5):547-52. PubMed ID: 10907947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04.
    Wolmark N; Rockette H; Mamounas E; Jones J; Wieand S; Wickerham DL; Bear HD; Atkins JN; Dimitrov NV; Glass AG; Fisher ER; Fisher B
    J Clin Oncol; 1999 Nov; 17(11):3553-9. PubMed ID: 10550154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leucovorin and fluorouracil vs levamisole and fluorouracil as adjuvant chemotherapy in rectal cancer.
    Tsavaris N; Gennatas K; Kosmas C; Skopelitis HM; Gouveris P; Dimitrakopoulos A; Zacharakis M; Kouraklis G; Vasiliou J; Felekouras E; Voros D; Zografos G; Balafouta M; Paraskevaidis M; Safioleas M; Fotiadis K; Papastratis G; Karatzas G; Papalambros E
    Oncol Rep; 2004 Oct; 12(4):927-32. PubMed ID: 15375524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic overview of chemotherapy effects in colorectal cancer.
    Ragnhammar P; Hafström L; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial.
    Arkenau HT; Bermann A; Rettig K; Strohmeyer G; Porschen R;
    Ann Oncol; 2003 Mar; 14(3):395-9. PubMed ID: 12598344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer.
    Kelsen DP; Saltz L; Cohen AM; Yao TJ; Enker W; Tong W; Tao Y; Bertino JR
    Cancer; 1994 Oct; 74(8):2224-33. PubMed ID: 7922973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma.
    Scheithauer W; Kornek GV; Marczell A; Karner J; Salem G; Greiner R; Burger D; Stöger F; Ritschel J; Kovats E; Vischer HM; Schneeweiss B; Depisch D
    Br J Cancer; 1998 Apr; 77(8):1349-54. PubMed ID: 9579845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
    O'Connell MJ; Laurie JA; Kahn M; Fitzgibbons RJ; Erlichman C; Shepherd L; Moertel CG; Kocha WI; Pazdur R; Wieand HS; Rubin J; Vukov AM; Donohue JH; Krook JE; Figueredo A
    J Clin Oncol; 1998 Jan; 16(1):295-300. PubMed ID: 9440756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04).
    Mamounas E; Wieand S; Wolmark N; Bear HD; Atkins JN; Song K; Jones J; Rockette H
    J Clin Oncol; 1999 May; 17(5):1349-55. PubMed ID: 10334518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01.
    Porschen R; Bermann A; Löffler T; Haack G; Rettig K; Anger Y; Strohmeyer G;
    J Clin Oncol; 2001 Mar; 19(6):1787-94. PubMed ID: 11251010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
    Haller DG; Catalano PJ; Macdonald JS; O'Rourke MA; Frontiera MS; Jackson DV; Mayer RJ
    J Clin Oncol; 2005 Dec; 23(34):8671-8. PubMed ID: 16314627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
    Poplin EA; Benedetti JK; Estes NC; Haller DG; Mayer RJ; Goldberg RM; Weiss GR; Rivkin SE; Macdonald JS
    J Clin Oncol; 2005 Mar; 23(9):1819-25. PubMed ID: 15774775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.
    Moertel CG; Fleming TR; Macdonald JS; Haller DG; Laurie JA; Tangen CM; Ungerleider JS; Emerson WA; Tormey DC; Glick JH
    J Clin Oncol; 1995 Dec; 13(12):2936-43. PubMed ID: 8523058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion.
    Arkenau HT; Rettig K; Porschen R
    Int J Colorectal Dis; 2005 May; 20(3):258-61. PubMed ID: 15549327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant systemic therapy protocol for Dukes' B2 and C resectable colon carcinoma.
    Gennatas C; Mouratidou D; Androulakis G; Georgoulias V; Tsavaris N; Philippakis M; Michailakis E; Kalofonos C; Mpesmpeas S; Katsos J; Tsitoura M; Retalis G; Mallas E; Voros D; Andreadis C; Hatzistylianos G; Pisiotis C; Kamilarios D; Kakoliris S; Komporozos V; Kannas D; Legakis N; Mpatakis T; Ntamtsios J; Papaevangelou E; Peros G; Photopoulos A; Pouli A; Prigouris S; Samanidis L; Sakellariou V; Smyrniotis V; Polymeneas G; Vasiliou J; Athanasiou A; Papadimitriou J
    Tumori; 2002; 88(1):32-6. PubMed ID: 12004847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
    Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
    Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of levamisole in the adjuvant treatment of stage III colon cancer patients: a randomized trial of 5-fluorouracil and levamisole versus 5-fluorouracil alone.
    Cascinu S; Catalano V; Piga A; Mattioli R; Marcellini M; Pancotti A; Bascioni R; Torresi U; Silva RR; Pieroni V; Giorgi F; Catalano G; Cellerino R
    Cancer Invest; 2003; 21(5):701-7. PubMed ID: 14628428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC).
    Di Costanzo F; Sobrero A; Gasperoni S; Dogliotti L; Frassineti L; Falcone A; Lionetto R; Bruzzi P; Luppi G; Gallo L; Conte P; Comandone A; Turci D; Marzola M; Folco U; Pfanner E; Mestriner M; Boni C; Galli C; Tonato M; Rosso R;
    Ann Oncol; 2003 Sep; 14(9):1365-72. PubMed ID: 12954574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemotherapy for patients with resected Dukes' C and high-risk B2 colon cancer with fluorouracil and levamisole.
    Au E; Ang PT; Seow-Choen F; Soo KC; Low CH; Chng HC; Ng BK
    Ann Acad Med Singap; 1998 Sep; 27(5):733-7. PubMed ID: 9919352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective evaluation of toxicity in three different schedules of adjuvant chemotherapy for patients with resected colorectal cancer. TTD Spanish Cooperative Group.
    Sastre J; Navarro M; Aranda E; Fonseca E; Checa T; Alonso MC; Gallen M; Camps C; Antón A; Díaz-Rubio E
    Oncol Rep; 1999; 6(6):1421-4. PubMed ID: 10523723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.